I

Instituto Nacional de Pediatria | Clinical Research Support Unit | Mexico City, United States

Research site

(Unclaimed)

Location

Insurgentes Sur 3700-C, Mexico City, Ciudad de Mexico, Mexico

Site insights

Top conditions

Top treatments

Nusinersen

Tedizolid Phosphate

MK-1986-018

Doravirine

Gatifloxacin

Carfilzomib

MK-1986

Corifollitropin

PF-07321332

Pazufloxacin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 16 total trials

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER)

The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronaviru...

Enrolling

Corona Virus Infection

Covid19

Drug: Baricitinib

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experien...

Active, not recruiting

RSV Infection

Biological: Placebo

Biological: Clesrovimab

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 wee...

Enrolling

Human Immunodeficiency Virus (HIV) Infection

Drug: 2 NRTIs

Drug: Doravirine

Locations recently updated

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and e...

Enrolling

COVID-19

Drug: nirmatrelvir

Drug: ritonavir